Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Chan, S. L. [1 ]
Miksad, R. [2 ]
Cicin, I. [3 ]
Chen, Y. [4 ]
Klumpen, H. J. [5 ]
Kim, S. [6 ]
Lin, Z. Z. [7 ]
Youkstetter, J. [8 ]
Sen, S. [8 ]
Cheng, A-L. [9 ]
El-Khoueiry, A. B. [10 ]
Meyer, T. [11 ]
Kelley, R. K. [12 ]
Abou-Alfa, G. K. [13 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab Oncol South China, Hong Kong, Peoples R China
[2] Beth Israel Deaconess Med Ctr, Res Oncol, New York, NY USA
[3] Trakya Univ, Dept Med Oncol, Edirne, Turkey
[4] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
[5] AMC, Med Oncol, Amsterdam, Netherlands
[6] Ctr Hosp Reg Univ Besancon, Med Oncol, Besancon, France
[7] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[8] Exelixis Inc, Dept Oncol, Alameda, CA USA
[9] Natl Taiwan Univ Hosp, Canc Ctr, Taipei, Taiwan
[10] Univ Southern Calif, Norris Comprehens Canc Ctr, Med Oncol, Los Angeles, CA USA
[11] UCL, Dept Oncol, London, England
[12] USCSF Hellen Diller Family Comprehens Canc Ctr, Med, San Francisco, CA USA
[13] Mem Sloan Kettering Canc Ctr, Dept Oncol, 1275 York Ave, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
127P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Cainap, Calin
    Qin, Shukui
    Huang, Wen-Tsung
    Chung, Ik-Joo
    Pan, Hongming
    Cheng, Ying
    Kudo, Masatoshi
    Kang, Yoon-Koo
    Chen, Pei-Jer
    Toh, Han Chong
    Gorbunova, Vera
    Eskens, Ferry
    Qian, Jiang
    McKee, Mark D.
    Ricker, Justin L.
    Carlson, Dawn M.
    El Nowiem, Saied
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [42] Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Venerito, M.
    Kelley, R. K.
    Ryoo, B-Y
    Merle, P.
    Park, J-W
    Bolondi, L.
    Chan, S. L.
    Lim, H. Y.
    Baron, A.
    Parnis, F.
    Knox, J.
    Cattan, S.
    Yau, T.
    Lougheed, J. C.
    Milwee, S.
    El-Khoueiry, A. B.
    Cheng, A-L
    Meyer, T.
    Abou-Alfa, G. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 282 - 283
  • [43] Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).
    Kelley, Robin Kate
    Ryoo, Baek-Yeol
    Merle, Philippe
    Park, Joong-Won
    Bolondi, Luigi
    Chan, Stephen Lam
    Lim, Ho Yeong
    Baron, Ari David
    Parnis, Francis
    Knox, Jennifer
    Cattan, Stephane
    Yau, Thomas Cheung
    Lougheed, Julie
    Milwee, Steven
    El-Khoueiry, Anthony
    Cheng, Ann-Lii
    Meyer, Tim
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
    Meyer, T.
    Kelley, R. K.
    Mangeshkar, M.
    Cheng, A-L.
    El-Khoueiry, A. B.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [45] Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
    Yau, T.
    Meyer, T.
    Kelley, R. K.
    Mangeshkar, M.
    Cheng, A-L.
    El-Khoueiry, A. B.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [46] A Comparative Study between Platelet-Albumin-Bilirubin (PALBI) and Albumin-Bilirubin (ALBI) Grade in Predicting Overall Survival for Hepatocellular Carcinoma in Korea
    Song, Myeong Jun
    Lee, Soon Kyu
    HEPATOLOGY, 2018, 68 : 839A - 839A
  • [47] Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Yau, T.
    Merle, P.
    Rimassa, L.
    Ryoo, B-Y.
    Cicin, I.
    Harris, W. P.
    Banu, E.
    Sarker, D.
    Tan, B.
    van Vlierberghe, H.
    Sen, S.
    Love, C.
    Cheng, A-L.
    Meyer, T.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [48] Machine learning-based normal tissue complication probability model for predicting albumin-bilirubin (ALBI) grade increase in hepatocellular carcinoma patients
    Prayongrat, Anussara
    Srimaneekarn, Natchalee
    Thonglert, Kanokporn
    Khorprasert, Chonlakiet
    Amornwichet, Napapat
    Alisanant, Petch
    Shirato, Hiroki
    Kobashi, Keiji
    Sriswasdi, Sira
    RADIATION ONCOLOGY, 2022, 17 (01)
  • [49] Proton Beam Therapy for Treatment-Naive Hepatocellular Carcinoma and Prognostic Significance of Albumin-Bilirubin (ALBI) Grade
    Kim, Tae Hyun
    Kim, Bo Hyun
    Park, Joong-Won
    Cho, Yu Ri
    Koh, Young-Hwan
    Chun, Jung Won
    Oh, Eun Sang
    Lee, Do Yeul
    Lee, Sung Uk
    Suh, Yang-Gun
    Woo, Sang Myung
    Moon, Sung Ho
    Kim, Sang Soo
    Lee, Woo Jin
    CANCERS, 2022, 14 (18)
  • [50] Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial
    Waidmann, O.
    Abou-Alfa, G. K.
    Meyer, T.
    Cheng, A-L
    El-Khoueiry, A. B.
    Rimassa, L.
    Ryoo, B-Y
    Cicin, I
    Merle, P.
    Chen, Y. H.
    Park, J-W
    Blanc, J-F
    Bolondi, L.
    Klumpen, H-J
    Chan, S. L.
    Dadduzio, V
    Hessel, C.
    Borgman-Hagey, A. E.
    Schwab, G.
    Kelley, R. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 254 - 254
12345